Intellia Therapeutics, Inc.
NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.68
Price-3.70%
-$0.41
1Y
Price
Market Cap
$1.198b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-699.4%
EBITDA Margin-735.2%
Net Profit Margin-558.2%
Free Cash Flow Margin-699.4%
EBITDA Margin-735.2%
Net Profit Margin-558.2%
Free Cash Flow MarginRevenue
$66.092m
-0.6%
1y CAGR+9.5%
3y CAGR+21.6%
5y CAGREarnings
-$394.596m
+14.1%
1y CAGR+1.6%
3y CAGR-18.1%
5y CAGREPS
-$3.54
+18.7%
1y CAGR+11.3%
3y CAGR-7.3%
5y CAGRBook Value
$620.939m
$758.779m
Assets$137.840m
Liabilities$80.490m
DebtDebt to Assets
10.6%
-0.2x
Debt to EBITDAFree Cash Flow
-$363.625m
-16.3%
1y CAGR-2.5%
3y CAGR-18.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company